Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Lexaria Bioscience Corp (LEXX)

Lexaria Bioscience Corp (LEXX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 38,920
  • Shares Outstanding, K 17,453
  • Annual Sales, $ 460 K
  • Annual Income, $ -5,800 K
  • EBIT $ -6 M
  • EBITDA $ -6 M
  • 60-Month Beta 0.99
  • Price/Sales 83.13
  • Price/Cash Flow N/A
  • Price/Book 4.56

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 11/30/24
See More
  • Average Estimate -0.12
  • Number of Estimates 1
  • High Estimate -0.12
  • Low Estimate -0.12
  • Prior Year -0.13
  • Growth Rate Est. (year over year) +7.69%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.00 +11.50%
on 12/17/24
2.85 -21.75%
on 12/04/24
+0.03 (+1.36%)
since 11/20/24
3-Month
1.95 +14.36%
on 11/15/24
3.39 -34.25%
on 10/03/24
-1.03 (-31.60%)
since 09/20/24
52-Week
1.20 +85.83%
on 01/04/24
6.85 -67.45%
on 03/11/24
+0.93 (+71.54%)
since 12/20/23

Most Recent Stories

More News
Lexaria's Registered GLP-1 Study #4 Begins Dosing

Registered Phase-1b 12-week study will investigate safety, diabetes control, and weight loss

LEXXW : 0.7471 (+11.51%)
LEXX : 2.23 (+0.90%)
Lexaria Forms New Scientific Advisory Board

North American drug delivery development experts added to help guide Lexaria's strategic plans

LEXXW : 0.7471 (+11.51%)
LEXX : 2.23 (+0.90%)
Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience

Dr. Gibson joining Lexaria's new scientific advisor board

LEXXW : 0.7471 (+11.51%)
LEXX : 2.23 (+0.90%)
Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5

Positive results in recent animal study strongly support first-ever human investigation for DehydraTECH-liraglutide

LEXXW : 0.7471 (+11.51%)
LEXX : 2.23 (+0.90%)
Insider Purchase: Chief Executive Officer of $LEXX (LEXX) Buys 22,828 Shares

RICHARD CHRISTOPHER, the Chief Executive Officer of $LEXX ($LEXX), bought 22,828 shares of the company on 12-02-2024. This trade was reported by Quiver Quantitative using data from a recent SEC filing....

LEXX : 2.23 (+0.90%)
BTV Features these Stocks to Watch: Contango Ore, First Nordic Metals, Champion Iron, Prime Mining, Lexaria Bioscience, Osisko Development, West Red Lake Gold Mines, & Surge Battery Metals

Vancouver, British Columbia--(Newsfile Corp. - November 30, 2024) - On FOX Business News broadcast on Sunday, Dec 1, 2024 - BTV Business Television interviews emerging companies in the markets including:Cannot...

CTGO : 10.30 (+0.59%)
CIA.TO : 5.17 (+0.19%)
LEXX : 2.23 (+0.90%)
PRYM.TO : 1.46 (+0.69%)
Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs

Semaglutide being investigated for applications in heart disease, Alzheimer's, liver disease, and more

LEXXW : 0.7471 (+11.51%)
LEXX : 2.23 (+0.90%)
Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled

DehydraTECH-processed tirzepatide from Zepbound® is being tested in an oral dose format

LEXXW : 0.7471 (+11.51%)
LEXX : 2.23 (+0.90%)
ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria’s 12-Week GLP-1, Diabetes Animal Study

DehydraTECH-liraglutide and a select DehydraTECH-CBD formulation were the top performing groups in the Study outperforming the Rybelsus® control group in both body weight-loss, by 11.53% and 10.65% respectively,...

LEXXW : 0.7471 (+11.51%)
LEXX : 2.23 (+0.90%)
Positive Partial 12-Week Blood Sugar Results from Lexaria’s GLP-1 Diabetes Animal Study

DehydraTECH-liraglutide and select DehydraTECH-CBD formulations were the top performing blood sugar groups

LEXXW : 0.7471 (+11.51%)
LEXX : 2.23 (+0.90%)

Business Summary

Lexaria Bioscience Corp. provides drug delivery platforms. Its patented DehydraTECH(TM) drug delivery technology changes the way Active Pharmaceutical Ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules....

See More

Key Turning Points

3rd Resistance Point 2.35
2nd Resistance Point 2.30
1st Resistance Point 2.26
Last Price 2.23
1st Support Level 2.17
2nd Support Level 2.12
3rd Support Level 2.08

See More

52-Week High 6.85
Fibonacci 61.8% 4.69
Fibonacci 50% 4.03
Fibonacci 38.2% 3.36
Last Price 2.23
52-Week Low 1.20

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar